Physician profile
James Lamb
NPI 1427411537
$16,294.75
in general payments reported to CMS, 2019-2025
46 companies · $1,814 in 2025
The $1,814 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $576 · 2021: $1,496 · 2022: $8,862 · 2023: $1,374 · 2024: $1,614 · 2025: $1,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,511 · Travel and Lodging: $224 · Education: $66.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,511.14 |
| Travel and Lodging | $223.55 |
| Education | $66.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $6,987.91 | 2021-2024 | Nuplazid |
| Abbvie INC. | $1,199.78 | 2021-2025 | |
| Ucb, INC. | $798.58 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Biogen, INC. | $665.73 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Sk Life Science, INC. | $579.50 | 2020-2024 | |
| Pfizer INC. | $450.75 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $385.61 | 2020-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Lilly USA, LLC | $360.06 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Novartis Pharmaceuticals Corporation | $345.31 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $317.34 | 2022-2025 | Ingrezza, Ongentys |
| Genentech USA, INC. | $305.79 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Amgen INC. | $292.78 | 2020-2023 | Aimovig |
| Alexion Pharmaceuticals, INC. | $286.56 | 2019-2025 | Ultomiris |
| Lundbeck LLC | $279.06 | 2020-2023 | Vyepti |
| Amneal Pharmaceuticals LLC | $254.21 | 2021-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lamb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.